BioSpace News Archive

In terms of revenue, the global ileostomy market is projected to expand at a CAGR of ~7% during the forecast period, due to numerous factors, about which, TMR offers comprehensive insights and forecasts in the global Ileostomy market report.

Industrial microbiology encompasses the use of microorganisms and their metabolites for a wide variety of industrial products.

Polyclonal antibodies are potentially powerful tools in a wide range of biomedical and biochemical research, world over.

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today presented preclinical data supporting its lead artificial antigen-presenting cell (aAPC) program, RTX-321, for the potential treatment of HPV 16-positive tumors at the American Society of Gene and Cell Therapy 23rd Annual Meeting. The meeting is being he

Seattle Plastic Surgeon Creates Mini Facelift That Makes Face Look 10 Years Younger

Marken announced that their Direct-to-Patient distribution services are now actively delivering to and from 94 cities in India and are expected to be available in 110 cities by the end of May.

Prevencio to leverage its HART AI platform to develop blood test for diagnosis of Kawasaki disease—a critical childhood disease—which can be triggered by COVID-19

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter 2020, as well as anticipated corporate milestones for 2020. “I am pleased to report that Surface has made substantial clinical progress to date in 2020; achieving important milestones with both of our hig

Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at the UBS Global Healthcare Conference on Monday, May 18, 2020 at 10:00 a.m. ET. The conference will be held in a virtual meeting format. Webcast information for this event will be accessible on the Eve

Toronto Innovation Acceleration Partners, Evotec SE and AmorChem II Fund L.P. are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide.